NCT01202812 - A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Sickle Cell DiseaseHEMOGLOBIN SSHemoglobin S Beta-0 ThalassemiaInflammationQuality of Life

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.

OTHER

Placebo Capsules

Placebo capsules given by mouth daily for 6 months.

Trial Locations (2)

Thomas Jefferson University Hospital, Philadelphia

St. Christopher's Hospital for Children, Drexel University, Philadelphia